NCT02326051

Timing of Initiation of LMWH Administration in Pregnant Women With APS

Timing of Initiation of Low Molecular Weight Heparin Administration in Pregnant Women With Antiphospholipid Syndrome

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Mohamed Sayed Abdelhafez · Academic / Other
• Sex: Female
• Age: 20 Years – 38 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of the effect of altering the timing of initiation of low molecular weight heparin (LMWH) administration on the pregnancy outcomes in women with antiphospholipid syndrome (APS)

Detailed description

Women will be randomly divided into two groups; one will start Enoxaparin therapy once positive pregnancy test is established and the other will start Enoxaparin therapy after sonographic confirmation of fetal cardiac pulsation. In all women, Enoxaparin will be given in a dose of 40 mg/day subcutaneously and the therapy will continue until termination of pregnancy

Conditions

• Recurrent Miscarriage
• Antiphospholipid Syndrome

Interventions

Type	Name	Description
DRUG	Enoxaparin	Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
DRUG	Enoxaparin	Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy

Timeline

• Start date: 2014-12-01
• Primary completion: 2017-02-01
• Completion: 2017-05-01
• First posted: 2014-12-25
• Last updated: 2017-11-29

Locations

2 sites across 1 country: Egypt